“Multiple Cardiac Rhabdomyomas in a Newborn Successfully Treated with a TOR inhibitor: A Case Report”
Keywords:
Cardiac rhabdomyoma, Tuberous sclerosis complex, Neonate, Everolimus, mTOR inhibitors, Cardiac tumors, Ventricular arrhythmia, Prenatal diagnosisAbstract
Introduction:Cardiac rhabdomyomas are the most common primary cardiac tumors in neonates and are strongly associated with tuberous sclerosis complex (TSC). While most lesions regress spontaneously, extensive or multifocal tumors may lead to ventricular dysfunction, arrhythmias, or hemodynamic compromise, prompting consideration of targeted therapy with mammalian target of rapamycin (mTOR) inhibitors.
Case Report:We report a male neonate born at 36 weeks’ gestation with prenatally detected intracardiac masses. Postnatal echocardiography revealed multiple large cardiac rhabdomyomas diffusely involving all cardiac chambers, causing marked reduction in ventricular cavity size, biventricular diastolic dysfunction, and moderate pericardial effusion, with preserved outflow tracts. Brain magnetic resonance imaging demonstrated multiple subependymal tubers, confirming the diagnosis of TSC. Everolimus therapy was initiated early in the neonatal period. After three doses, a significant reduction in tumor size and improvement in ventricular function were observed. The infant developed frequent ventricular arrhythmias, which were successfully controlled with low-dose sotalol. Follow-up echocardiography at one month showed marked further regression of the rhabdomyomas and sustained clinical stability.
Discussion:This case illustrates the role of cardiac rhabdomyomas as an early diagnostic marker of TSC and supports the effectiveness of mTOR inhibition in achieving rapid tumor regression in neonates with extensive cardiac involvement. However, the persistence of arrhythmias despite significant tumor reduction suggests that electrical abnormalities may not parallel structural improvement, highlighting the need for continued rhythm surveillance and adjunctive antiarrhythmic therapy.
Conclusion:Early recognition of TSC-associated cardiac rhabdomyomas and prompt initiation of Everolimus can result in rapid tumor regression and functional improvement, potentially avoiding surgical intervention. Comprehensive multidisciplinary follow-up remains essential to address ongoing cardiac and neurological risks and to better define the long-term safety of mTOR inhibitors in neonates.
Downloads
References
[1] Peng L, Cai Y, Wu J, et al. Prenatal diagnosis and clinical management of cardiac rhabdomyoma: a single-center study. Front Cardiovasc Med. 2024;11:1340271. Published 2024 Feb 16. doi:10.3389/fcvm.2024.1340271
[2] Almuqbil M, Aldoohan W, Alhinti S, et al. Review of the spectrum of tuberous sclerosis complex: The Saudi Arabian Experience. Neurosciences (Riyadh). 2024;29(2):113-121. doi:10.17712/nsj.2024.2.20230061
[3] Benyounes N, Fohlen M, Devys JM, Delalande O, Moures JM, Cohen A. Cardiac rhabdomyomas in tuberous sclerosis patients: a case report and review of the literature. Arch Cardiovasc Dis. 2012;105(8-9):442-445. doi:10.1016/j.acvd.2012.01.009
[4] Northrup H, Aronow ME, Bebin EM, et al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol. 2021;123:50-66. doi:10.1016/j.pediatrneurol.2021.07.011
[5] Sugalska M, Tomik A, Jóźwiak S, Werner B. Treatment of Cardiac Rhabdomyomas with mTOR Inhibitors in Children with Tuberous Sclerosis Complex-A Systematic Review. Int J Environ Res Public Health. 2021;18(9):4907. Published 2021 May 5. doi:10.3390/ijerph18094907
[6] Eticha TG, Ararso R, Sultan S, et al. Isolated Asymptomatic Fetal Intracardiac Mass: A Case of Rhabdomyoma. Int Med Case Rep J. 2023;16:97-102. Published 2023 Feb 28. doi:10.2147/IMCRJ.S402663
[7] Pereira M, Magalhães T, Vilan A, Pimenta J, Antunes Sarmento J. Everolimus for cardiac rhabdomyomas in neonate with tuberous sclerosis complex and significant arrhythmias. Prog Pediatr Cardiol. 2025;77:101812. doi:10.1016/j.ppedcard.2025.101812
[8] Doğan V, Yeşil Ş, Kayalı Ş, et al. Regression of symptomatic multiple cardiac rhabdomyomas associated with tuberous sclerosis complex in a newborn receiving everolimus. J Trop Pediatr. 2015;61(1):74-77. doi:10.1093/tropej/fmu056
[9] Nir-David Y, Brosilow S, Khoury A. Rapid response of a cardiac rhabdomyoma causing severe right ventricular outflow obstruction to Sirolimus in an infant with negative genetics for Tuberous sclerosis. Cardiol Young. 2021;31(2):312-314. doi:10.1017/S1047951120003819
[10] Tiberio D, Franz DN, Phillips JR. Regression of a cardiac rhabdomyoma in a patient receiving everolimus. Pediatrics. 2011;127(5):e1335-e1337. doi:10.1542/peds.2010-2910
[11] Zöllner JP, Franz DN, Hertzberg C, et al. A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC). Orphanet J Rare Dis. 2020;15(1):23. Published 2020 Jan 21. doi:10.1186/s13023-019-1258-3
[12] Padalino MA, Vida VL, Boccuzzo G, et al. Surgery for primary cardiac tumors in children: early and late results in a multicenter European Congenital Heart Surgeons Association study. Circulation. 2012;126(1):22-30. doi:10.1161/CIRCULATIONAHA.111.037226
[13] Shibata Y, Maruyama H, Hayashi T, et al. Effect and Complications of Everolimus Use for Giant Cardiac Rhabdomyomas with Neonatal Tuberous Sclerosis. AJP Rep. 2019;9(3):e213-e217. doi:10.1055/s-0039-1692198
[14] Mustafa HJ, Javinani A, Morning ML, et al. Characteristics and Outcomes of Fetal Cardiac Rhabdomyoma With or Without mTOR Inhibitors, a Systematic Review and Meta-Analysis. Prenat Diagn. 2024;44(10):1251-1267. doi:10.1002/pd.6640
[15] Barnes BT, Procaccini D, Crino J, et al. Maternal Sirolimus Therapy for Fetal Cardiac Rhabdomyomas. N Engl J Med. 2018;378(19):1844-1845. doi:10.1056/NEJMc1800352
[16] Jawad A, Hannouneh ZA, Salame H, Jaber R, Eid N. Solitary atrial Rhabdomyoma in an infant with tuberous sclerosis: a case report and review of the literature. BMC Cardiovasc Disord. 2023;23(1):597. Published 2023 Dec 7. doi:10.11
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
